Mechanism of Action

Dapagliflozin propanediol is an SGLT2 inhibitor that targets the sodium-glucose cotransporter 2 in the proximal renal tubules. By inhibiting SGLT2, it decreases glucose reabsorption from the tubular lumen, lowers the renal threshold for glucose, and promotes urinary glucose excretion, which helps to lower blood glucose levels in patients with type 2 diabetes.

Indication

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, similar to the indication for Dapagliflozin.